Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-Blind, Randomized, Multi-Center, Adaptive Dose-Ranging, Placebo-Controlled, Parallel-Group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-Remitting Multiple Sclerosis. [FOR EXTENSION STUDY SEE 7000230025]

Next Previous
Trial Profile

A Phase II, Double-Blind, Randomized, Multi-Center, Adaptive Dose-Ranging, Placebo-Controlled, Parallel-Group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-Remitting Multiple Sclerosis. [FOR EXTENSION STUDY SEE 7000230025]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms BOLD
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 13 Oct 2012 Results assessing the correlation between magnetic resonance imaging and lymphocyte counts presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
  • 13 Oct 2012 Primary analysis presented at the28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top